文献速递神经核医学肿瘤 PET/CT

CXCR4靶向[¹⁸F]AlF-NOTA-QHY-04 PET/CT在原发性中枢神经系统淋巴瘤中的前瞻性对比研究

CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-04-30

该前瞻性研究纳入29例疑似原发性中枢神经系统淋巴瘤(PCNSL)患者,对比[¹⁸F]AlF-NOTA-QHY-04 PET/CT与增强MRI及[¹⁸F]FDG PET/CT的诊断效能。结果显示,[¹⁸F]AlF-NOTA-QHY-04 PET/CT敏感性和准确率与增强MRI相当,显著优于[¹⁸F]FDG PET/CT,且肿瘤/背景比值(TBR)显著更高。

要点

  • [¹⁸F]AlF-NOTA-QHY-04 PET/CT诊断PCNSL的敏感性和准确率与增强MRI相当。
  • 该显像剂TBR-SUVmax中位数42.75,显著高于[¹⁸F]FDG的1.07。
  • 其诊断效能显著优于[¹⁸F]FDG PET/CT,有望用于PCNSL诊断与再分期。

核心结论

  • [¹⁸F]AlF-NOTA-QHY-04 PET/CT在PCNSL中呈现高肿瘤/背景对比,诊断准确率与增强MRI相当且显著优于[¹⁸F]FDG PET/CT。

研究设计与样本

  • 新诊断病灶以活检病理为参考标准,复发评估采用基于增强MRI、临床随访及脑脊液检查的复合参考标准。

主要发现

  • 确诊6例初治患者(14个病灶)和16例复发患者(16个病灶),另有7例无复发。
  • 在20例同时接受两种PET的患者中,[¹⁸F]AlF-NOTA-QHY-04的SUVmax中位数显著低于[¹⁸F]FDG(2.42 vs. 11.73,P < 0.001),但TBR-SUVmax中位数显著更高(42.75 vs. 1.07,P < 0.001)。
  • [¹⁸F]AlF-NOTA-QHY-04 PET/CT识别出更多阳性病灶(14 vs. 7,P = 0.023)。
  • 相对复合参考标准,[¹⁸F]AlF-NOTA-QHY-04 PET/CT的敏感性和准确率分别为87.50%和90.91%,与增强MRI(均为100%)相当(P > 0.05),显著优于[¹⁸F]FDG PET/CT(43.75%和59.09%,P = 0.023)。
  • ROC分析显示[¹⁸F]AlF-NOTA-QHY-04 SUVmax为最佳诊断参数(AUC = 0.979)。

关键数值与推荐

  • 诊断效能对比:敏感性87.50% vs. 43.75%(P = 0.023),准确率90.91% vs. 59.09%(P = 0.023)。
  • SUVmax中位数2.42 vs. 11.73(P < 0.001),TBR-SUVmax中位数42.75 vs. 1.07(P < 0.001)。
  • 最佳诊断参数SUVmax的AUC为0.979。

临床怎么用

  • 对于疑似PCNSL患者,[¹⁸F]AlF-NOTA-QHY-04 PET/CT可提供与增强MRI相当的诊断准确性,并显著优于[¹⁸F]FDG PET/CT。
  • 该显像剂高TBR特性有助于在低脑背景中识别更多阳性病灶,可能适用于初诊和复发再分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to evaluate the diagnostic performance of [¹⁸F]AlF-NOTA-QHY-04 PET/CT, a novel CXCR4-targeted imaging agent, in detecting primary central nervous system lymphoma (PCNSL) at initial diagnosis and suspected recurrence, in comparison with contrast-enhanced magnetic resonance imaging (CE-MRI) and [¹⁸F]FDG PET/CT. METHODS: We prospectively enrolled patients with suspected PCNSL between September 2022 and December 2024. A total of 29 patients underwent both CE-MRI and [¹⁸F]AlF-NOTA-QHY-04 PET/CT, with 20 patients also receiving [¹⁸F]FDG PET/CT. Biopsy pathology served as the reference standard for newly diagnosed lesions. Recurrence was assessed using a composite reference standard based on CE-MRI, clinical follow-up, and cerebrospinal fluid (CSF) findings when available; an exploratory sensitivity analysis excluded MRI-dependent cases. Imaging parameters including the maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and tumor-to-background ratios (TBR) were calculated. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis and compared. RESULTS: Six treatment-naïve patients (14 lesions) and 16 patients with recurrence (16 lesions) were confirmed, along with 7 patients without recurrence. Both primary and recurrent lesions showed intense tracer uptake on [¹⁸F]AlF-NOTA-QHY-04 PET/CT, characterized by notably high TBR. In the 20-patient subgroup undergoing both PET scans, [¹⁸F]AlF-NOTA-QHY-04 demonstrated significantly lower absolute SUVmax compared to [¹⁸F]FDG (median: 2.42 vs. 11.73, P < 0.001) but a substantially higher TBR-SUVmax (median: 42.75 vs. 1.07, P < 0.001), leading to the identification of more positive lesions (14 vs. 7, P = 0.023). Relative to the composite reference standard, [¹⁸F]AlF-NOTA-QHY-04 PET/CT achieved sensitivity and accuracy (87.50% and 90.91%, respectively) comparable to CE-MRI (100% for both, P > 0.05) and significantly superior to [¹⁸F]FDG PET/CT (43.75% and 59.09%, P = 0.023). ROC analysis identified [¹⁸F]AlF-NOTA-QHY-04 SUVmax as the optimal diagnostic parameter (AUC = 0.979). CONCLUSION: [¹⁸F]AlF-NOTA-QHY-04 PET/CT demonstrated high tumor-to-background contrast in PCNSL, consistent with its low background brain uptake. It shows diagnostic accuracy comparable to CE-MRI and significantly superior to [¹⁸F]FDG PET/CT, demonstrating high potential as a valuable imaging tool for the diagnosis and restaging of PCNSL.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pang Y, Xing L, Liu J, et al. CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 42056569. doi:10.1007/s00259-026-07905-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。